针对HML-2的抗体反应可能在肌萎缩侧索硬化中具有保护作用
研究分析243例ALS、242名健康供者和85例多发性硬化个体的HML-2抗体反应,发现ALS患者识别的HML-2 env肽段更多、抗体水平更高,且低抗体水平与明确诊断及较低预测和实际生存相关。
要点
- ALS患者血清识别的HML-2 env肽段数量多于健康对照(p<0.0001)。
- 55.14%的ALS患者、21.16%健康供者和13.10%多发性硬化个体有针对HML-2肽段的抗体(AUC=0.769,p<0.0001)。
- ALS患者中HML-2抗体水平较低与EL Escorial标准明确诊断(p=0.03)、较低预测生存(p=0.02)和实际生存(p=0.03)相关。
核心结论
- ALS患者和对照者对HML-2 env特定表位存在差异抗体反应,提示表位扩展,可能因病毒基因再激活后持续抗原暴露所致。
- ALS中低水平HML-2 env抗体与不良预后和较低生存概率相关。
研究设计与样本
- 研究分析了243例ALS患者、242名健康供者和85例多发性硬化个体的血清抗体。
- 采用肽阵列进行表位定位、肽酶联免疫吸附试验(ELISA)检测HML-2 env抗体,并用数字聚合酶链反应(PCR)分析HML-2胞外水平。
主要发现
- ALS患者血清识别的HML-2 env肽段数量多于健康对照(p<0.0001)。
- ALS患者HML-2水平高于健康供者(p=0.02)。
- ALS患者针对特定HML-2 env肽段的抗体水平高于健康供者或多发性硬化个体(p<0.0001)。
- 55.14%的ALS患者、21.16%的健康供者和13.10%的多发性硬化个体有针对HML-2肽段的抗体(AUC=0.769,p<0.0001)。
- 血清中胞外HML-2 DNA水平(p=0.02)和ALS血清识别的HML-2 env肽段数量(p=0.02)与疾病持续时间相关;ALS患者中较低HML-2抗体水平与EL Escorial标准明确诊断(p=0.03)、较低预测生存(p=0.02)和实际生存(p=0.03)相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Reactivation of HERV-K(HML-2) has been found in subsets of individuals with amyotrophic lateral sclerosis (ALS). This study examines the antibody response against HML-2 in ALS and analyzes its clinical relevance. METHODS: Antibodies to HML-2 envelope (env) were analyzed using a peptide array for epitope mapping and by a peptide enzyme-linked immunosorbent assay (ELISA) in 242 healthy donors, and 243 ALS and 85 multiple sclerosis (MS) individuals. Extracellular levels of HML-2 were analyzed by digital polymerase chain reaction (PCR). RESULTS: Antibodies in the sera of ALS individuals recognized more HML-2 env peptides compared to healthy controls (p < 0.0001). ALS individuals had higher levels of HML-2 than healthy donors (p = 0.02) and higher antibody levels against a select HML-2 env peptide compared to healthy donors or individuals with multiple sclerosis (p < 0.0001). 55.14% of ALS compared to 21.16% of healthy donors and 13.10% of MS individuals had antibodies against the HML-2 peptide (AUC = 0.769, p < 0.0001). Levels of extracellular HML-2 DNA in serum (p = 0.02) and the number of HML-2 env peptides recognized by ALS sera (p = 0.02) correlated with disease duration. Among ALS individuals, lower levels of HML-2 antibodies were associated with a definite diagnosis per EL Escorial criteria (p = 0.03), and with a lower predicted (p = 0.02) and observed survival (p = 0.03). INTERPRETATION: There is a differential antibody response against specific epitopes of HML-2 env in ALS and controls, suggesting epitope spreading, likely due to persistent antigenic exposure following reactivation of the viral genes. Low levels of antibodies to HML-2 env in ALS are associated with poor prognosis and decreased survival probability. ANN NEUROL 2022;92:782-792.
引用
- Garcia-Montojo M, Simula ER, Fathi S, et al. Antibody Response to HML-2 May Be Protective in Amyotrophic Lateral Sclerosis. Ann Neurol. 2022. PMID: 36053951. doi:10.1002/ana.26466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。